Study guide
2.3 Disease Indications & the Cellular Therapy Modality Map
Transplantation and Cellular Therapy Certified Nurse TCTCN
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 The TCTCN Credential: Rename, Scope & Official Test Blueprint 1.2 TCTCN Eligibility, Test-Day Logistics, Scoring & Renewal 1.3 Building the Study Plan & Clinical Prioritization Framework 1.4 Clinical Triage Rehearsal & Exam-Day Question Strategy
2 Chapter 2: Foundations of Transplantation & Cellular Biology
2.1 Hematopoietic Lineage, the MHC & HLA Class I vs Class II Biology 2.2 HLA Typing Resolution, Donor Matching, DSA & ABO Compatibility 2.3 Disease Indications & the Cellular Therapy Modality Map 2.4 Pre-Transplant Risk Stratification & Organ Suitability Assessment 2.5 Stem Cell & Cellular Product Sources: Donor Selection Hierarchy 2.6 Conditioning Regimens & Lymphodepletion Principles 2.7 Recipient and Caregiver Education Across the Continuum
3 Chapter 3: Product Collection, Processing & Infusion Procedures
3.1 Stem Cell Mobilization: Niche Biology, Agents & CD34+ Collection Targets 3.2 Apheresis Nursing Care: Vascular Access, Citrate Toxicity & Donor Safety 3.3 Graft Engineering, ABO-Directed Processing & Cryopreservation Science 3.4 DMSO Toxicity, Premedication & Time-Critical Thawed Product Administration 3.5 Pre-Administration Verification, Equipment & CAR T Infusion Readiness 3.6 Infusion Monitoring & Acute Reaction Differential Management 3.7 Engraftment Definitions, Kinetics & Factors Impairing Recovery 3.8 Graft Failure Classification & Donor Chimerism Tracking
4 Chapter 4: Acute Post-HSCT Complications & Graft-versus-Host Disease
4.1 Acute GVHD: Billingham's Postulates, Classification & the Ferrara 3-Phase Model 4.2 Acute GVHD Organ Manifestations, Histopathology & MAGIC Staging 4.3 MAGIC Overall Grading & Acute GVHD Plasma Biomarkers 4.4 Acute GVHD Prophylaxis, First-Line Steroids & Steroid-Refractory Therapy 4.5 SOS/VOD: Microvascular Pathophysiology & Risk Stratification 4.6 SOS/VOD Diagnostic Criteria, Surveillance & Defibrotide Therapy 4.7 TA-TMA: Complement Pathophysiology, Harmonized Criteria & Differential 4.8 TA-TMA Management, Complement-Directed Therapy & Other Endothelial Syndromes
5 Chapter 5: Post-Transplant Infections & Supportive Care
5.1 Neutropenic Fever, Pre-Engraftment Phase & Empiric Antimicrobial Therapy 5.2 CMV: Risk Stratification, Letermovir Prophylaxis & DNAemia Treatment 5.3 EBV/PTLD, HHV-6 Encephalitis, BK Cystitis, Adenovirus, HSV & VZV 5.4 Invasive Fungal Infections (Aspergillus, Candida, Mucor) & PJP Prophylaxis 5.5 Supportive Care in Aplasia: Transfusion Guidelines, Oral Mucositis & Nutrition
6 Chapter 6: Post-Cellular Therapy Management, CRS & ICANS
6.1 CAR Structural Architecture, Generations & Costimulatory Domain Biology 6.2 The Vein-to-Vein Lifecycle, In Vivo Kinetics & On-Target B-Cell Aplasia 6.3 CRS Pathophysiology, Clinical Kinetics & Inflammatory Biomarkers 6.4 ASTCT CRS Grading, Tocilizumab & Escalation Management 6.5 ICANS: Assessment, ICE Scoring & Clinical Management 6.6 Delayed Cellular Toxicities: Prolonged Cytopenias, B-Cell Aplasia & IEC-HS 6.7 Symptom Management and Functional Recovery After Cellular Therapy
7 Chapter 7: Chronic GVHD & Long-Term Survivorship
7.1 Chronic GVHD: Three-Phase Immunobiology & NIH Classification 7.2 Chronic GVHD Diagnostic Manifestations, BOS & NIH Global Severity Scoring 7.3 Chronic GVHD: Systemic, Steroid-Sparing & Multidisciplinary Therapy 7.4 Late Effects: Endocrine, Cardiovascular, Bone Health & Secondary Malignancies 7.5 Immune Reconstitution & the Inactivated Re-Vaccination Schedule 7.6 Live Vaccines, Household Contact Precautions & Survivorship Care Plans 7.7 Post-HSCT Relapse: Surveillance, Immunologic Manipulation & Treatment
8 Chapter 8: Quality of Life, Ethics & Professional Practice Standards
8.1 Psychosocial Trajectories, Distress Screening & Delirium Assessment 8.2 Caregiver Planning, Financial & Cultural Navigation, and Sexual Health 8.3 Palliative Care Integration, Advance Directives & Ethical Considerations 8.4 FACT-JACIE Quality Standards, CIBMTR / NMDP Reporting & Compliance 8.5 Evidence-Based Practice, Discharge Education & Quality Improvement
2.3 Disease Indications & the Cellular Therapy Modality Map
Key Takeaways Explain This Topic AI
Autologous HCT provides hematopoietic rescue after high-dose therapy for selected diseases; multiple myeloma, chemosensitive relapsed lymphoma and germ-cell tumors are major examples, but timing and eligibility depend on current disease guidance and alternatives.
Allogeneic HCT adds donor hematopoiesis and immune effects for selected malignant, marrow-failure, immune, hemoglobin and inherited disorders; disease biology/MRD, donor/platform, non-relapse risk and patient goals shape the decision.
CAR T-cell products targeting CD19 or BCMA are not interchangeable: construct, manufacturing, age range, disease indication, prior-therapy requirements, dosing, and toxicity instructions are all product-specific and change with supplemental approvals.
The cellular-therapy category extends beyond CAR T cells to tumor-infiltrating lymphocytes, natural killer-cell approaches, bispecific antibodies, gene-modified hematopoietic cells, and donor lymphocyte infusions; their sources, manufacturing, administration, and toxicity patterns differ.
A bispecific antibody is an administered drug that redirects the patient's own T cells, not a collected and manufactured cell product, so its step-up dosing and monitoring workflow differs fundamentally from CAR T therapy.
Last updated: September 2026
Disease Indications, Staging & Pre-Transplant Risk Stratification
Quick Clinical Summary: Determining transplant or cellular-therapy suitability balances disease biology, treatment goal, prior therapy, organ reserve, infection risk, performance, psychosocial resources, donor or product feasibility, and patient preferences. Autologous HCT supplies marrow rescue after intensive therapy; allogeneic HCT adds a donor immune effect. CAR T, TIL, NK-cell approaches, bispecific antibodies, gene-modified therapies, and DLI differ in source, mechanism, timing, and toxicity. HCT-CI informs risk but does not dictate eligibility or conditioning intensity by itself.
1. Autologous HCT: Treatment Logic and Indications
Autologous HCT permits high-dose therapy followed by reinfusion of the patient’s collected hematopoietic cells. It avoids allogeneic GVHD and does not provide a donor graft-versus-malignancy effect. Major indications include transplant-eligible multiple myeloma; selected relapsed lymphomas with chemosensitive disease; selected germ-cell tumors; and a smaller set of severe autoimmune diseases in specialized programs. Disease era, prior therapy, response, comorbidity, fertility goals and availability of CAR T or other alternatives determine timing. Age, one PET response, or one renal-dose rule is not an automatic eligibility boundary.
2. Allogeneic HCT: Treatment Logic and Indications
Allogeneic HCT provides donor hematopoiesis plus immune-mediated graft-versus-malignancy or immune-system replacement. It is used in selected acute leukemias, MDS/MPN and myelofibrosis, severe aplastic anemia, marrow-failure syndromes, hemoglobinopathies, primary immune deficiencies and other inherited disorders. The choice depends on disease genetics and measurable residual disease, remission/response, nontransplant alternatives, donor/platform, expected relapse and non-relapse risk, organ and functional reserve, infection, access and patient goals.
Examples are conditional: adverse-risk AML or persistent MRD can strengthen an allogeneic recommendation; a matched-sibling graft can be preferred in selected severe aplastic anemia; and gene therapy may compete with allogeneic HCT for selected hemoglobinopathies. Confirm the current disease guideline rather than turning an example into a universal transplant indication.
3. CAR T-Cell Therapies: FDA-Approved Products & Indications
Chimeric Antigen Receptor (CAR) T-cell therapy involves collecting autologous T lymphocytes via leukapheresis, genetically engineering them ex vivo with a viral vector to express a synthetic receptor targeting a tumor-surface antigen, expanding them, and re-infusing them following lymphodepleting chemotherapy.
Target and disease family Product examples High-yield distinction
CD19 B-cell malignancies Axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, lisocabtagene maraleucel Products differ in construct, manufacturing, age range, disease indication, prior-therapy requirements, dosing, and toxicity instructions; they are not interchangeable.
BCMA multiple myeloma Idecabtagene vicleucel, ciltacabtagene autoleucel Prior-therapy requirements and safety instructions are product-specific and can change with supplemental approvals.
Label discipline: FDA indications evolve faster than certification guides. For a real patient, verify the current prescribing information rather than inferring eligibility from target antigen or a memorized line-of-therapy rule.
4. Cellular Therapy Modalities Beyond CAR T
The outline expects more than a list of CAR T products. Link each modality to its source, mechanism, and nursing workflow:
Modality What it does Nursing and assessment implications
Tumor-infiltrating lymphocytes (TILs) Autologous lymphocytes are harvested from tumor, expanded, and reinfused after lymphodepletion; some regimens include cytokine support. Coordinate tumor procurement and manufacturing, assess fitness for lymphodepletion/supportive therapy, and monitor capillary leak, infection, cytopenia, and organ toxicity per product/regimen.
NK-cell therapy Uses innate cytotoxic cells from autologous, allogeneic, cord, or engineered sources. Source and construct determine persistence, compatibility, conditioning, and toxicity surveillance; do not assume every NK product follows a commercial CAR T pathway.
Bispecific antibody Redirects a patient's endogenous T cells by binding CD3 and a tumor antigen; it is an administered drug, not a collected cell product. Step-up dosing, infection/cytopenia risk, CRS and neurologic monitoring, and outpatient eligibility are product- and protocol-specific.
Gene-modified hematopoietic cells Autologous stem cells are edited or transduced to correct or compensate for disease biology, then infused after conditioning. Preserve chain of identity, teach infertility and conditioning risks, monitor engraftment, and support required long-term follow-up for gene-modified products.
Donor lymphocyte infusion (DLI) Donor lymphocytes augment graft-versus-malignancy or address selected mixed-chimerism situations after allogeneic HCT. Balance intended immune effect against GVHD and marrow-aplasia risk; confirm disease/chimerism context and ordered dose.
5. Matching the Modality to the Clinical Question
Candidates who can define each modality still lose items that ask what changes for the patient and the nurse when one is chosen over another. Two comparisons carry most of that weight.
Autologous HCT versus CAR T for the same relapsed lymphoma patient. Both begin with an apheresis collection, and there the similarity ends. Autologous HCT delivers high-dose conditioning with the collected cells as marrow rescue: the toxicity is regimen-related - mucositis, prolonged aplasia, infection during the neutropenic window - and it is delivered on a schedule the program controls. CAR T delivers a living drug after lymphodepletion: the toxicity is immune-mediated and clusters in the first two to four weeks as CRS, ICANS, and prolonged cytopenias, the treatment calendar depends on a manufacturing slot the program does not control, and the patient must remain near the treating center under product-specified restrictions. The caregiver burden, the monitoring plan, the emergency teaching, and the long-term follow-up obligations differ accordingly.
Allogeneic HCT versus gene therapy for a hemoglobinopathy. Both require conditioning and both aim at durable correction, but allogeneic HCT introduces a donor immune system with its graft-versus-host disease risk, its immunosuppression, and its donor availability constraint, while an autologous gene-modified product removes GVHD risk and the donor search but adds manufacturing dependency, its own conditioning toxicity including infertility, and mandated long-term follow-up for the gene-modified product. Teaching, consent, and survivorship planning diverge substantially even though the conditioning experience looks similar from the bedside.
The generalizable rule for the exam is that modality determines the toxicity window, the calendar, the setting, and the follow-up obligation - and stems usually test one of those four, not the mechanism.